Camber Capital Management’s Denali Therapeutics DNLI Stock Holding History

Camber Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$5.6M	Sell	400,000 -850,000	-68%	-$12M	0.53%	22
2025 Q1	$17M	Sell	1,250,000 -1,000,000	-44%	-$19.2M	0.6%	25
2024 Q4	$45.9M	Buy	2,250,000 +250,000	+13%	+$6.4M	1.06%	20
2024 Q3	$58.3M	Hold	2,000,000	–	–	1.85%	18
2024 Q2	$46.4M	Buy	2,000,000 +500,000	+33%	+$9.6M	1.29%	21
2024 Q1	$30.8M	Buy	+1,500,000	New	+$28.2M	0.75%	23

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Camber Capital Management's DNLI Position: Q2 2025 in Review

Camber Capital Management reduced its Denali Therapeutics (DNLI) stake by 68% in Q2 2025, selling an estimated $12M and leaving 400,000 shares worth $5.6M. The position accounts for 0.53% of the portfolio, ranked #22.

Camber Capital Management first reported a position in DNLI in Q1 2024 and has held it in 6 quarters since. The position peaked at $58.3M in Q3 2024. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

Camber Capital Management held 400,000 shares of Denali Therapeutics worth $5.6M as of Q2 2025.
Camber Capital Management sold 850,000 Denali Therapeutics shares in Q2 2025, an estimated $12M.
Denali Therapeutics made up 0.53% of Camber Capital Management's portfolio in Q2 2025, its #22 holding.
Camber Capital Management first reported a position in Denali Therapeutics in Q1 2024 and has held it in 6 quarters since.
Camber Capital Management's Denali Therapeutics position peaked at $58.3M in Q3 2024.
230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.